Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534089 | 0.95 | TDP1 (0.48) | TDP1ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL19286018 | 0.87 | TDP1 (0.38) | TDP1 | |
| SCHEMBL25523468 | 0.87 | TDP1 (0.42) | TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL17471829 | 0.86 | TDP1 (0.41) | TDP1LMNA | |
| SCHEMBL4398781 | 0.85 | TDP1 (0.54) | TDP1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL25779313 | 0.85 | TDP1 (0.48) | TDP1ALDH1A1TSHRLMNAHSD17B10 | |
| Propene SCHEMBL15205012 | 0.85 | TDP1 (0.41) | TDP1ALDH1A1HSD17B10 | |
| SCHEMBL11460313 | 0.85 | ALDH1A1 (0.50) | TDP1ALDH1A1TSHRHSD17B10THRB | |
| SCHEMBL11459642 | 0.85 | ALDH1A1 (0.50) | TDP1ALDH1A1TSHRHSD17B10THRB | |
| SCHEMBL14378379 | 0.85 | TDP1 (0.41) | TDP1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145387-A1 | RESIN CONTAINING OXETANE AND EPOXY GROUPS AND RESIN COMPOSITION INCLUDING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-05-26 | — | — | US | disclosed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100184603-A1 | Alcohol alkoxylates, compositions containing these, and use of the alcohol alkoxylates as adjuvants for the agrochemical field | BASF SE (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2150515-A1 | ALCOHOL ALKOXYLATES, AGENTS CONTAINING THESE, AND USE OF THE ALCOHOL ALKOXYLATES AS ADJUVANTS FOR THE AGROCHEMICAL FIELD | BASF SE (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008132150-A1 | ALCOHOL ALKOXYLATES, AGENTS CONTAINING THESE, AND USE OF THE ALCOHOL ALKOXYLATES AS ADJUVANTS FOR THE AGROCHEMICAL FIELD | BASF SE (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | TDP1 159/4885ALDH1A1 588/4885TSHR 4547/4885 |
| US-20100184603-A1 | Alcohol alkoxylates, compositions containing these, and use of the alcohol alkoxylates as adjuvants for the agrochemical field | ACOX3, PAOX, ADH5 | TDP1 4027/4885ALDH1A1 930/4885TSHR 3414/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | TDP1 210/4885ALDH1A1 642/4885TSHR 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.